Anticoagulant management in the cardiovascular setting

Fundamental and Clinical Pharmacology

Volumn 26, Issue 1, 2012, Pages 11-15

  Verheugt, Freek W A ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Acute coronary syndrome; Atrial fibrillation; Rivaroxaban; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; FIBRINOPEPTIDE A; PROTHROMBIN; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EMBOLISM; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HEMORRHAGE; HUMANS; THROMBOSIS; VITAMIN K;

EID: 84855663263     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00979.x     Document Type: Review

References (26)

1. Mark D.B., Peterson E.D. Health economics of acute coronary syndromes. J. Thromb. Thrombolysis (1998) 5 S161-S168.
2. Brouwer M.A., van den Bergh P.J., Aengevaeren W.R. et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation (2002) 106 659-665.
3. Merlini P.A., Bauer K.A., Oltrona L. et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 90 61-68.
4. Rothberg M.B., Celestin C., Fiore L.D., Lawler E., Cook J.R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern. Med. (2005) 143 241-250.
5. Dantas G.C., Thompson B.V., Manson J.A., Tracy C.S., Upshur R.E. Patients' perspectives on taking warfarin: qualitative study in family practice. BMC Fam. Pract. (2004) 5 15-23.
6. Mega J.L., Braunwald E., Mohanavelu S. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 374 29-38.
7. Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur. Heart J. (2010) 31 2369-2429.
8. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch. Intern. Med. (1987) 147 1561-1564.
9. Singer D.E., Albers G.W., Dalen J.E. et al. Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest (2008) 133 546S-592S.
10. Lin H.J., Wolf P.A., Kelly-Hayes M. et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 27 1760-1764.
11. World Health Organization. Global burden of stroke, in: Mackay J., Menash G. (Eds), The Atlas of Heart Disease and Stroke. World Health Organization, Geneva, Switzerland, 2004, [accessed 2010 November 18].
12. Allender S., Scarborough P., Peto V. et al. European cardiovascular disease statistics: 2008 edition. [accessed 2010 October 18].
13. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA (2001) 285 2864-2870.
14. Fuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with Atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European heart rhythm association and the heart rhythm society. Circulation (2006) 114 e257-e354.
15. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. (2007) 146 857-867.
16. Connolly S.J., Pogue J., Hart R.G. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. (2009) 360 2066-2078.
17. Pisters R., van Oostenbrugge R.J., Knottnerus I.L. et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 12 779-784.
18. Harenberg J. New anticoagulants in atrial fibrillation. Semin. Thromb. Hemost. (2009) 35 574-585.
19. ACTIVE Investigators. Randomized controlled trial of clopidogrel plus aspirin versus oral anticoagulation in patients with atrial fibrillation: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE). Lancet (2006) 367 1903-1912.
20. SPORTIF-III III Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (SPORTIF-III): randomised controlled trial. Lancet (2003) 362 1691-1698.
21. Albers G.W., Diener H.C., Frison L. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 293 690-698.
22. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. (2009) 361 1139-1151.
23. Connolly S.J., Ezekowitz M., Yusuf S., Reilly P.A., Wallentin L., for the RE-LY Investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med. (2010) 363 1875-1876.
24. The Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban - Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. (2010) 159 340-347.
25. Amadeus Investigators, Bousser M.G., Bouthier J. et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet (2008) 371 315-321.
26. Hacke W., Patel M.R., Becker R.C. et al. Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies. 19th European Stroke Conference (2010). Abstract OAID 5.